reflecting challenging macro demand trends in China. Competitive Headwinds: Considering QIAGEN’s huge gamut of services, the company is facing increasing competition from firms that provide ...

China, as you know, Qiagen has a small or relatively small exposure to China, it’s between 5% and 6% of our business. We always said over the last three years, that we do not believe that the ...

reflecting challenging macro demand trends in China. Recording more than 50% of its revenues from the international market, QIAGEN is highly exposed to the risk of foreign currency movement.

QIAGEN (Suzhou) Translational Medicine Co. (TMC) Ltd. is the first diagnostic R&D company focused on translational science in China. The company provides complete solutions for precision medicine ...

QIAGEN has announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks ...

operating income margin improvement of at least 150 basis points VENLO, The Netherlands, February 05, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced ...